| Excerpt | Relevance | Reference |
|---|
| "Enalapril treatment in the chronic model, however, protected against cardiac dysfunction and cardiomyocyte atrophy and was associated with increased activation of the PI3K/AKT/mTOR pathway along with normal levels of CTGF." | 5.48 | Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. ( Basquin, D; Hullin, R; Maillard, M; Martin, D; Métrich, M; Regamey, J; Sarre, A, 2018) |
| "Enalapril treatment in the chronic model, however, protected against cardiac dysfunction and cardiomyocyte atrophy and was associated with increased activation of the PI3K/AKT/mTOR pathway along with normal levels of CTGF." | 1.48 | Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. ( Basquin, D; Hullin, R; Maillard, M; Martin, D; Métrich, M; Regamey, J; Sarre, A, 2018) |